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Infectious diseases have shaped the human population genetic structure,
and genetic variation inﬂuences the susceptibility to many viral diseases. However, a
variety of challenges have made the implementation of traditional human Genomewide Association Studies (GWAS) approaches to study these infectious outcomes challenging. In contrast, mouse models of infectious diseases provide an experimental
control and precision, which facilitates analyses and mechanistic studies of the role of
genetic variation on infection. Here we use a genetic mapping cross between two
distinct Collaborative Cross mouse strains with respect to severe acute respiratory syndrome coronavirus (SARS-CoV) disease outcomes. We ﬁnd several loci control differential disease outcome for a variety of traits in the context of SARS-CoV infection.
Importantly, we identify a locus on mouse chromosome 9 that shows conserved synteny with a human GWAS locus for SARS-CoV-2 severe disease. We follow-up and conﬁrm a role for this locus, and identify two candidate genes, CCR9 and CXCR6, that
both play a key role in regulating the severity of SARS-CoV, SARS-CoV-2, and a distantly related bat sarbecovirus disease outcomes. As such we provide a template for
using experimental mouse crosses to identify and characterize multitrait loci that regulate pathogenic infectious outcomes across species.
IMPORTANCE Host genetic variation is an important determinant that predicts disease outcomes following infection. In the setting of highly pathogenic coronavirus
infections genetic determinants underlying host susceptibility and mortality remain
unclear. To elucidate the role of host genetic variation on sarbecovirus pathogenesis and disease outcomes, we utilized the Collaborative Cross (CC) mouse genetic
reference population as a model to identify susceptibility alleles to SARS-CoV and
SARS-CoV-2 infections. Our ﬁndings reveal that a multitrait loci found in chromosome 9 is an important regulator of sarbecovirus pathogenesis in mice. Within this
locus, we identiﬁed and validated CCR9 and CXCR6 as important regulators of host
disease outcomes. Speciﬁcally, both CCR9 and CXCR6 are protective against severe
SARS-CoV, SARS-CoV-2, and SARS-related HKU3 virus disease in mice. This chromosome 9 multitrait locus may be important to help identify genes that regulate coronavirus disease outcomes in humans.
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sarbecoviruses
tudies support the hypothesis that natural host genetic variation contributes substantially to microbial susceptibility and disease severity (1, 2). However, the speciﬁc genes
and alleles that regulate differential disease outcomes to respiratory virus infections remain
largely unknown. The viral family Coronaviridae is comprised of several human and animal
pathogens, and at least ﬁve zoonotic coronaviruses (CoV) have emerged or rapidly
expanded their geographic range in mammals in the 21st century (3, 4). To date, the most
signiﬁcant human pathogens include the group 2B sarbecoviruses (severe acute respiratory syndrome coronavirus [SARS-CoV] and SARS-CoV-2), which likely emerged from bats
to cause human epidemic or pandemic outbreaks of severe acute respiratory infections,
leading to substantial morbidity and mortality (5, 6). Many other high-risk group 2B SARSlike viruses including bat sarbecoviruses (BtCoV), group 2C Middle East respiratory coronavirus (MERS-CoV), and MERS-like bat CoVs also appear poised to cause future human
epidemics or pandemics (7–9). Emerging sarbecoviruses vary widely in their ability to
cause human and animal disease (10). The 2003 SARS-CoV strain caused ;8,000 infections
and ;800 deaths leading to a 10% mortality rate, whereas SARS-CoV-2 has infected .500
million humans, leading to over 6.2 million deaths in an ongoing pandemic (11, 12). SARSCoV and SARS-CoV-2 demonstrate a broad host range with the ability to cause variable
disease outcomes that range from asymptomatic infection to death in other mammals,
raising questions whether common underlying host genes contribute to disease across
species (13). While the 2003 SARS-CoV had a higher mortality rate compared to SARS-CoV2, COVID-19 outcomes can vary from asymptomatic to life-threatening acute respiratory
disease syndrome and death in humans, supporting a documented role for viral and interhost genetic control of disease severity (14–17). Mapping the underlying natural host gene
variation that regulates susceptibility and disease severity after diverse sarbecovirus infections and across multiple species is expected to reveal common genetic loci that regulate
pathogenic outcomes, inform threat and risk potential, lead to reﬁned small animal models
of human disease, and reveal novel targets for therapeutic interventions.
Mouse-adapted SARS-CoV and SARS-CoV-2 cause disease in mice by inducing acute
respiratory distress syndrome (ARDS) and recapitulating several aspects of COVID-19
pathogenesis including age-dependent severe disease (18, 19). Mouse genetic reference
populations (GRPs) also have been employed as highly relevant models of human disease
and used to identify host susceptibility loci and genes, as well as gene networks and
higher level interactions that regulate phenotypic variation and disease severity. Among
mouse GRPs, the Collaborative Cross (CC) has over 44 million single nucleotide polymorphisms (SNPs) and 4 million insertions and deletions (InDels), which segregate between
the eight founder strains (20). In addition, several thousand novel variants (SNPs and small
indels, as well as large deletions) exist within individual CC strains (21–24). As such, the CC
population models human genetic diversity with both common and rare variants poised
to impact a variety of phenotypes, including disease severity after acute viral infections,
like inﬂuenza virus, ﬂaviviruses, ﬁloviruses, and coronaviruses (20, 25–31).
In this study, we leveraged the CC model to characterize the genetic susceptibility
landscape of sarbecovirus infections in mice. We demonstrated that multiple loci regulate the host disease responses to this subgroup of coronaviruses. Speciﬁcally, we identiﬁed two genes Ccr9 and Cxcr6 within a multitrait QTL located on chromosome 9
(Chr9), which have natural polymorphisms driving altered expression levels that correlate with SARS-CoV and SARS-CoV-2 disease severity in mice. This QTL shows conserved synteny with a locus in humans on Chr3 (which includes Ccr9 and Cxcr6) that
was identiﬁed in COVID-19 human Genome-wide Association Studies (GWAS) predicting severe outcome and hospitalization. In total, several GWAS in humans have identiﬁed a common locus on Chr3 (3p21.31), that identiﬁed six genes associated with
COVID-19 severity, susceptibility, respiratory failure, and risk of hospitalization and
included CCR9 and CXCR6 (14, 15, 32–34). In addition, across these human studies there
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RESULTS
Variable disease phenotypes after CC-RI strain infection. To extend our previous
understanding of how genetic variation contributes to differential SARS-CoV outcomes,
we studied groups of female mice from ﬁve different CC strains (CC005/TauUnc,
CC011/Unc, CC020/TauUnc, CC068/TauUnc, and CC074/Unc) infected with 2003 SARSCoV using our SARS-CoV MA15 model, which recapitulates many of the disease outcomes reported in humans (35). As these strains did not segregate alleles at previously
identiﬁed SARS QTL, differences in disease would be due to uncharacterized genetic
differences (27, 28). Infected mice were followed for weight loss and possible mortality
through 4 days postinfection (Fig. 1A). We observed a wide variation of weight loss
across these strains. Due to divergent disease susceptibilities to SARS-CoV MA15 and
narrow variation within a given strain, we focused on the disease-resistant CC011/Unc
(hereafter CC011, ,5% weight loss) and the highly susceptible CC074/Unc strain (hereafter CC074, .15% weight loss). To assess disease progression in these strains in
greater detail, we challenged additional groups of CC011 and CC74 mice (of both
sexes) with SARS-CoV MA15. CC074 mice showed severe disease by 4 days postinfection (dpi) marked by ;80% mortality of ;80% in 2 separate experiments, and a .15%
loss of body weight. In contrast, CC011 had a maximal weight loss of 5% body weight
and 100% survival (Fig. 1B and C). Despite differences in weight loss, mortality, and
congestion score, both strains had high levels of virus detectable in lungs at 2 and
4 dpi (Fig. 1D and E, respectively; mean ;5  106 PFU/lobe, CC011 n = 6; CC074 n = 1,
5 mice died). While conﬁrming the original observation that these two strains exhibit
distinct disease susceptibilities, these results also suggested that differences in host
immune responses, rather than viral burden, drive the different disease outcomes in
these strains.
SARS-CoV MA15 CC-F2 screen. To identify the genetic basis of the observed disease outcomes and SARS-CoV pathogenesis, we generated a large F2 intercross
between CC011 and CC074 (n = 403 F2 mice, both males and females). F2 mice were
inoculated intranasally at 9 to 12 weeks of age with 1  104 PFU of SARS-CoV MA15.
To expand our understanding of response to SARS-CoV infection, in addition to standard SARS-CoV-associated phenotypes including weight loss, viral burden, mortality,
and lung congestion (Fig. 2A to D), we also examined circulating immune cells as well
as lung function (Fig. 2E to G). Across these phenotypes, we observed an expanded
range of disease responses in the F2 cross relative to their parent CC strains, (Fig. 2 and
Fig. S1). While a signiﬁcant fraction of the F2 population (approximately 25%) died or
were euthanized, this was diminished compared to CC074 (;80% mortality).
Concurrent with viral challenge, the F2 animals were genotyped with the
MiniMUGA array and QTL mapping in R/QTL conducted (36, 37). We identiﬁed a total
of 2,750 markers segregating between CC011 and CC074 among the autosomes and
X-chromosome. These markers were well distributed across the genome (23 to
48,228,264 nucleotides between markers, median = 509,769 nucleotides between
markers). Using this genetic map, we identiﬁed a total of ten genetic loci segregating
in this F2 population for a variety of traits (host response to SARS HrS24-28 at genomewide, P , 0.05; HrS29-33, P , 0.1) (Fig. S1 and Table 1). Signiﬁcant loci included a
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was a high amount of genetic variation as well as different lead SNPs in this region,
suggesting that multiple genes may regulate disease associations and severity. Our
concordant susceptibility proﬁles of the CC011 and CC074 parent mouse lines, as well
as Ccr9- and Cxcr6-deﬁcient mice infected with SARS-CoV MA15, SARS-CoV-2 MA10 or
BtCoV HKU3-SRBD MA, demonstrate involvement of this locus in severe COVID-19 disease susceptibility across species and across different sarbecoviruses, as well as highlighting the utility of preemergence disease models. Our results also demonstrate that
the CC mouse panel is well suited to identify and validate relevant susceptibility
regions for other human infectious and chronic diseases, while providing focus for a
deeper understanding of emerging sarbecovirus disease patterns in animal and human
populations.

mBio

FIG 1 CC strains demonstrate different susceptibility to SARS-CoV infection and disease. Age-matched female
mice (n = 4) of 5 different CC strains (CC005, CC011, CC020, CC068, and CC074) were infected with 1  104
PFU and monitored for weight loss until 4 dpi. An additional group of age-matched CC011 and CC074 (both
sexes) were infected with 1  104 PFU, and mice were monitored for disease progression until 4 dpi. (A)
Weight loss for CC strains CC005, CC011, CC020, CC068, and CC074. (B) Weight loss of the two parental CC
strains CC011 and CC074. (C) Percentage survival of the two parental CC strains CC011 and CC074. (D) Lung
viral titer of the two parental CC strains CC011 and CC074 on 2 and 4 dpi. (E) Lung congestion score of the
two parental CC strains CC011 and CC074 (female 10- to 12-week-old mice were infected with 1  104 PFU
SARS-CoV MA15; CC011: n = 4 for 2 dpi and n = 6 for 4 dpi; CC074: n = 4 for 2 dpi and n = 6 for 4 dpi,
respectively). Data were analyzed using Mann-Whitney test (lung titer and congestion scores); *, P , 0.05.

multitrait locus (Hrs26, Chr 9), as well as single loci associated with overall mortality
(HrS24, Chr4), weight loss in males at 4 dpi (HsR25, Chr4), peripheral lymphocyte and
neutrophil levels at 4 dpi (Hrs27, Chr11), and ﬁnally, altered pulmonary function (PenH)
at 2 dpi (Hrs28, Chr15). The suggestive loci were identiﬁed in contributing to altered
weight loss, mortality, and altered lung function phenotypes (Table 1).
The multitrait HrS26 had a major impact on clinical disease (odds ratio [OR] of 3.15
for mortality), as well as lung pathology 10.24% of overall population variation) including
lung function (7.76% of respiratory resistance (PenH) and immune cell inﬂammation
July/August 2022 Volume 13 Issue 4
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FIG 2 Disease phenotypes after SARS-CoV MA15 infection in the CC011xCC074-F2 mice. The 10-to 12-week-old CC011xCC074-F2 mice (n = 403; 226 males,
177 females) were generated and infected with 1  104 PFU of SARS-CoV MA15 and followed for 4 days to record clinical disease outcomes. (A)
Congestion score of CC011xCC074-F2 mice at 4 dpi. (B) Weight loss of CC011xCC074-F2 mice. (C) Lung viral titer of CC011xCC074-F2 mice at 4 dpi. (D)
Percentage survival of CC011xCC074-F2 mice over the time of infection. (E) Percentage of peripheral blood lymphocytes of CC011xCC074-F2 mice at 4 dpi.
(F) Percentage of peripheral blood neutrophils of CC011xCC074-F2 mice at 4 dpi. (G) PenH (airway resistance) of CC011xCC074-F2 mice at 2 dpi.

(11.8% of neutrophils and 12.39% of lymphocyte variation) (Fig. S1 and Table 1). As such,
it represents a locus of major effect driving disease differences between these strains following SARS-CoV MA15 challenge.
CC011 and CC074 disease outcomes following SARS-CoV-2 MA10 infection.
Concurrent with our ongoing analyses to phenotype SARS-CoV MA15 infection outcomes in CC parental and F2 strains, SARS-CoV-2 suddenly emerged. Although SARSCoV-2 was genetically distinct with about 22% nucleotide differences across the
genome compared to SARS-CoV (6), the two viruses provided an opportunity to test
whether similar host genes regulated pathogenesis across distinct sarbecoviruses.
Accordingly, we infected CC011 and CC074 with the SARS-CoV-2 MA10 strain, which
shares many of the COVID-19 disease phenotypes seen in human patients (Fig. 3) (18).
Importantly, the parental strains showed similar clinical disease phenotypes after
SARS-CoV-2 MA10 infection (Fig. 3A to D) and SARS-CoV MA15 (Fig. 1B to E). Despite a
small difference in weight loss and lung viral load between both virus strains, CC074
showed the same severe disease phenotypes with severe weight loss, lung discoloration scores, and 100% mortality by 4 dpi after infection with SARS-CoV-2 MA10 (Fig. 3).
These results suggested that the QTL identiﬁed for SARS-CoV susceptibility might also
be relevant for SARS-CoV-2-induced disease.
July/August 2022 Volume 13 Issue 4
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TABLE 1 List of QTLs mapped with CC011xCC074-F2
Phenotypic
variation (%)

Chromosome (Mb)

Phenotype(s) (days postinfection [dpi])

Haplotype(s)a

chr4: 32.95–114.54

Mortality

HrS25

chr4: 6.38–17.97

Weight loss in males (4 dpi)

HrS26

chr9: 74.94–124.06
chr9: 117.38–124.07
chr9: 116.24–124.07
chr9: 111.54–122.63
chr9: 111.54–122.63
chr11: 26.44–80.76
chr11: 17.89–80.76
chr15: 58.66–74.04

Mortality
Congestion score (4 dpi)
PenH (2 dpi)
Periph. neutrophils (4 dpi)
Periph. lymphocytes (4 dpi)
Periph. neutrophils (4 dpi)
Periph. lymphocytes (4 dpi)
PenH (2 dpi)

CC011: G, H, C
CC074: A/H, A/D, D, E, F
CC011: G, B
CC074: A
CC011: B, G
CC074: A

chr3: 7.2–159.1

Mortality (4 dpi)
Congestion score (4 dpi)
Weight loss (4 dpi)
Mortality (4 dpi)
Weight loss females (4 dpi)
Hemorrhage (4 dpi)
Periph. monocytes (4 dpi)
PenH (2 dpi)

QTL iD
CC011xCC074-F2, signiﬁcant loci
HrS24

HrS27
HrS28

CC011xCC074-F2, suggestive loci
HrS29
HrS30

chr9: 28.2–124.1

HrS31

chr13: 31.9–90.3

HrS32

chr14: 33.8–114.8

HrS33

chrX: 6.2–93.9

Rpef (2 dpi)
Periph. neutrophils (2 dpi)

CC011: H, B, H
CC074: C
CC011: H
CC074: B

ORb 4.34
12.57%
ORb 3.15
10.24%
7.76%
11.8%
12.39%
5.5%
5.6%
8.48%

CC011: C, C/D, D, A, D, E
CC074: D, H, B, B/F, B/D, B
CC011: B, G, B
CC074: A
CC011: B, C
CC074: G, D
CC011: C
CC074: E, H, G
CC011: E, C/E, E, A, G
CC074: G, B

aHaplotype

Identiﬁcation of a multitrait QTL on Chr9. Recently, several reports have identiﬁed
a common locus in humans on Chr3 (3p21.31) that is associated with COVID-19 severity, susceptibility, and risk of hospitalization (14, 15, 32–34). This locus, encompassing
genes such as SLC6A20, LZTFL1, FYCO1, XCR1, CXCR6, and CCR9, shows conserved synteny with the proximal region of the multitrait locus mapped on Chr9 in mice (HsR26
and HsR30) (Fig. 4A and Table 1). In addition, the studies in humans conﬁrmed a high
degree of polymorphism in this area on Chr3. We examined the sequence differences
between CC011 and CC074 in this region of conserved synteny, where CC011 possessed a PWK/PhJ haplotype and CC074 had an A/J haplotype, and detected several
SNPs and polymorphisms (Table 2) (38). Ccr9 and Fyco1 have missense SNPs in coding
regions and all other SNPs were in regulatory regions such as the 59 and 39 untranslated region, at splice sites, and within introns, pointing toward differential expression
of these target genes (Table 2). Similar ﬁndings and altered gene expression levels
have been reported in the human GWAS, transcriptome-wide association study, and
epigenetic studies involving these gene sets (15, 16, 39–41).
Consequently, gene expression proﬁles of Ccr9, Cxcr6, Xcr1, Lztf1, Fyco1, and Slc6a20a/b
were measured in the lungs of infected CC011 and CC074. Signiﬁcantly reduced expression of Ccr9, Cxcr6, and Lztf1 was observed in highly susceptible CC074 mice (P , 0.005),
compared to the resistant CC011 mice. In contrast, expression of Fyco1 was signiﬁcantly
upregulated (P , 0.05) in CC074 compared to the CC011 mice, while levels of Xcr1 and
Slc6a20a/b expression were not signiﬁcantly different (Fig. 4B). We took advantage of
RNAseq data from unperturbed CC mice that contained either the protective (PWK) or susceptible (A/J) haplotype at this locus to determine the expression of these six genes
(Table S1). We found signiﬁcant differences in expression of Lztf1 (increased in A/J), Fyco1
July/August 2022 Volume 13 Issue 4
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effects are described for each QTL. For the Pre-CC and CC-RIX, the haplotypes are separated based on the allele effect splits between founder haplotypes (A, A/J;
B, C57BL/6J; C, 129S1/SvImJ; D. NOD/ShILtJ; E, NZO/HiLtJ; F, CAST/EiJ; G, PWK/PhJ; H, WSB/EiJ). In CC-F2 crosses, the haplotypes listed are those present in the given parent
strains from the proximal to distal ends of each region. Rpef, ratio of time to peak expiratory ﬂow relative to total expiratory time.
bQTL inﬂuencing mortality calculate an odds ratio (OR) for disease rather than a % of variation explained. For both the CC-RIX and the CC-F2, OR for speciﬁc loci are
calculated with a full model of all mortality loci, to better estimate their independent effects.

mBio

FIG 3 CC011 and CC074 disease outcomes after mouse-adapted SARS-CoV-2 infection. Groups of parental
CC011 and CC074 mice were infected with 1  104 PFU of SARS-CoV-2 MA10 and followed for several days for
clinical disease outcomes. (A) Weight loss of the two parental CC strains CC011 and CC074. (B) Lung viral titer
of the two parental CC strains CC011 and CC074 on 2 and 4 dpi. (C) Percentage survival of the two parental
CC strains CC011 and CC074. (D) Lung congestion score of the two parental CC strains CC011 and CC074
(female 10- to 12-week-old mice were infected with 1  104 PFU SARS-CoV-2 MA10; CC011: n = 6 for 2 dpi and
n = 13 for 4 dpi; CC074: n = 6 for 2 dpi and n = 15 for 4 dpi, respectively). Data were analyzed using 2-way
ANOVA with multiple comparison (weight and PenH), log-rank (survival), and Mann-Whitney test (lung titer and
congestion scores); **, P , 0.005.

(decreased in A/J), and Slc6a20a/b (increased in A/J), as well as a trend for Xcr1 (increased
in A/J). Together, these data suggest a complex cis-regulatory architecture of these genes
at baseline along with induction in the context of infection.
Ccr9 regulates sarbecovirus infection and pathogenesis in vivo. The sarbecoviruses are divided into three phylogenetic clades designated clade Ia (SARS-CoV), clade
II (HKU3) and clade Ib (SARS-CoV-2) (Fig. 5A). To initially examine the impact of differences in gene expression have on virus disease phenotypes, we focused on Ccr9 and
Cxcr6, which were differentially expressed by the respective mouse strains (Fig. 4B).
Knockout mice have the engineered construct introduced in a cell line (typically derived
from a 129 mouse) before being bred to a relevant control strain. We genotyped our CCR9
and CXCR6ko mice with the genome-wide MiniMUGA genotyping array. We conﬁrmed that
both strains were largely (all ,99.5%) of the relevant genetic background (C57BL/6NJ for
CCR9 and C57BL/6J for CXCR6), with a small cluster of SNPs differing at the distal chromosome 9 locus where the knocked-out genes are located. These SNPs were consistent with a
129 genetic background, thus conﬁrming how these knockout strains were created.
To ensure that the presence of a 129 haplotype at the locus itself was not causal for
disease differences, we identiﬁed three CC strains which contained a 129 haplotype at
this locus (CC039, CC041, and CC065) and assessed the response to SARS-CoV2 in these
three strains relative to CC011 and CC074 mice (Fig. S2). While these three strains
July/August 2022 Volume 13 Issue 4
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showed a range of disease responses from mild weight loss to mortality, the fact that
there was not a consistent disease response in these strains suggest that the 129 haplotype at HrS26 is not informative for SARS-CoV2 disease. As such, when contrasting
knockouts to relevant controls, we can be conﬁdent that the results are due to the targeted mutation itself and not an artifact of the haplotype the mutation was generated
in. Therefore, we infected Ccr9 deﬁcient mice (CCR92/2) of both sexes as well as the relevant age-matched C57BL/6NJ controls with SARS-CoV MA15. CCR92/2 mice showed
enhanced susceptibility relative to control mice. The latter was marked by signiﬁcant
weight loss of .20% (HrS30), high viral load in the lungs and severe lung pathology,
prolonged respiratory dysfunction as measured by whole body plethysmography (HrS26),
increased lung congestion scores (HrS26), and elevated mortality (HrS30) (Fig. 5B to F). In
addition to SARS-CoV, we also studied the role of CCR9 in clinical disease outcomes using
a mouse adapted HKU3-SRBD MA (Fig. 5G to I) (10). We infected CCR92/2 mice and
C57BL/6NJ control mice with 1  105 PFU of a clade II HKU3-SRBD MA chimeric virus and
monitored daily weight and other clinical measures of disease (10). CCR92/2 mice demonstrated signiﬁcantly increased weight loss compared to wild-type mice beginning at
4 dpi. CCR92/2 lungs on 4 and 7 dpi also showed greater pathology than wild-type controls (P , 0.005 and P , 0.05, respectively). In contrast to SARS-CoV MA15 infections,
HKU3-SRBD MA virus titers on 4 dpi were not signiﬁcantly different between CCR92/2 and
wild-type mice, with all animals clearing infectious virus by 7 dpi. These data support the

TABLE 2 SNPs in CC011 and CC074 possible target genes in the Chr9 multitrait QTLa (38)
Variants
Missense
59 UTR
39 UTR
Intron
Splicing
aCC011,

SCL6A20A/B
8
7

LZTFL1
1
33
139
2

CCR9
3
12
57
699
3

FYCO1
20
7
729
424
4

CXCR6

XCR1

3
34

2
34
36

PWK; CC074, A/J; UTR, untranslated region.
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FIG 4 Identiﬁcation of a Multitrait QTL on Chr9. Each of the individual F2 mice were genotyped using MiniMuga and QTL mapping conducted by testing
the strength of association between each F2 mouse’s phenotype and their genotypes at each marker. (A) A quantitative multitrait locus with major effect
was identiﬁed on Chr9 (74.9–124 Mb), which affected mortality, weight loss, lung congestion, lung function, and peripheral hematology. CC011/Unc has a
C57BL/6/PWK haplotype and CC074/Unc has an A/J/PWK haplotype in this QTL region. (B) Expression levels of Ccr9, Cxcr6, Xcr1, Lztﬂ1, Fyco1, and Slc6a20a/
b of SARS-CoV-2 MA10-infected CC011 and CC074 mice at 4 dpi, determined by quantitative RT-PCR, normalized to Gapdh (female 10- to 12-week-old mice
were infected with 1  104 PFU SARS-CoV-2 MA10; CC011: n = 5, CC074: n = 5). Data were analyzed using Mann-Whitney test; *, P , 0.05; **, P , 0.005.

mBio

FIG 5 Validation of Ccr9 as susceptibility gene during SARS-CoV MA15 and HKU3-SRBD MA infection. To validate CCR9 as a susceptibility gene during
SARS-CoV infection, groups of age-matched CCR92/2 mice were infected with 1  105 PFU SARS-CoV MA15 and HKU3-SRBD MA and followed for several
days for disease outcomes. The Spike protein sequences of selected Sarbecoviruses were aligned and phylogenetically compared. Sequences were aligned
using free end gaps with the Blosum62 cost matrix, and the tree was constructed using the neighbor-joining method with a Jukes-Cantor genetic distance
model based on the multiple sequence alignment in Geneious Prime. The GenBank accession numbers for each genome sequence are shown. The tree was
then output and visualized using EvolView. (A) Phylogenetic tree of sarbecoviruses. The Spike protein sequences of selected sarbecoviruses were aligned and
phylogenetically compared. Sequences were aligned using free end gaps with the Blosum62 cost matrix, and the tree was constructed using the neighborjoining method with a Jukes-Cantor genetic distance model based on the multiple sequence alignment in Geneious Prime. The GenBank accession numbers
for each genome sequence are shown. The tree was then output and visualized using EvolView (bold indicates viruses tested). (B) Weight loss of CCR92/2
mice and C57BL/6NJ control mice. (C) Lung viral titer of CCR92/2 mice and C57BL/6NJ control mice on 4 and 6 dpi. (D) PenH of CCR92/2 mice and C57BL/6NJ
control mice. (E) Congestion of CCR92/2 mice and C57BL/6NJ control mice on 4 and 6 dpi. (F) Percentage survival of CCR92/2 mice and C57BL/6NJ control
mice. (G) Weight loss of CCR92/2 mice and C57BL/6NJ control mice. (H) Lung viral titer of CCR92/2 mice and C57BL/6NJ control mice on 4 and 7 dpi. I. Lung
congestion of CCR92/2 mice and C57BL/6NJ control mice on 4 and 7 dpi (15-18-week-old mice were infected with 1  105 PFU SARS-CoV MA15; C57BL/6NJ:
n = 5 for 4 dpi and n = 5 for d6pi; CCR92/2: n = 4 for 4 dpi and n = 4 for 6 dpi, respectively; C57BL/6NJ: n = 10 and CCR92/2: n = 12 for survival study). Data
were analyzed using Mann-Whitney test; *, P , 0.05; **, P , 0.005 (15- to 18-week-old mice were infected with 1  105 PFU HKU3-SRBD MA; C57BL/6NJ:
n = 4 for 4 dpi and n = 5 for 6 dpi; CCR92/2: n = 5 for 4 dpi and n = 6 for 6 dpi, respectively). Data were analyzed using 2-way ANOVA with multiple
comparison (weight and PenH), log-rank (survival), and Mann-Whitney test (viral titer, congestion score); *, P , 0.05; **, P , 0.005; ***, P , 0.0005.

hypothesis that null or low-level expression of CCR9 likely contributes to the multitrait
QTL disease phenotypes noted following clade Ia and clade II sarbecovirus infections.
Clade Ib SARS-CoV-2 MA10 infection in CCR92/2 mice also developed more severe
clinical disease including greater weight loss (P , 0.0001 to P , 0.05) (Fig. 6A) and
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FIG 6 Ccr9 Regulates sarbecovirus infection and pathogenesis in vivo. To study the effect of Ccr9 on the susceptibility to SARS-COV-2 infection, groups of
age-matched CCR92/2 mice were infected with 1  105 PFU SARS-CoV-2 MA10 and followed for several days for disease outcomes. (A) Weight loss of
CCR92/2 mice and C57BL/6NJ control mice. (B) Lung viral titer of CCR92/2 mice and C57BL/6NJ control mice on 2, 4, 6, and 14 dpi. (C) PenH of CCR92/2
mice and C57BL/6NJ control mice. (D) cytokine/chemokine distribution in the lung of CCR92/2 mice and C57BL/6NJ control mice on 2, 4, and 6 dpi. (E)
Composition of lung inﬁltrating immune cells in the lung of CCR92/2 mice and C57BL/6NJ control mice on 4 and 6 dpi (15- to 18-week-old mice were
infected with 1  105 PFU SARS-CoV-2 MA10; C57BL/6NJ: n = 29, n = 4 for 2 dpi, n = 7 for 4 dpi, n = 15 for 6 dpi, and n = 3 for 14 dpi; CCR92/2: n = 24
total, n = 4 for 2 dpi, n = 7 for 4 dpi, n = 10 for 6 dpi, and n = 3 for 14 dpi, respectively, for weight loss and viral titer, C57BL/6NJ: n = 4 and CCR92/2:
n = 4 lung function analysis, 57BL/6NJ: n = 4 for 2 dpi, n = 4 for 4 dpi, n = 15 for 6 dpi; CCR92/2: n = 4 for 2 dpi, n = 4 for 4 dpi; n = 11 for 6 dpi for

(Continued on next page)
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virus titers (P , 0.0005) (Fig. 6B) than C57BL/6NJ mice. Furthermore, infected CCR92/2
mice displayed increased PenH respiratory dysfunction (P , 0.0005 to P , 0.005)
(Fig. 6C), lung congestion (P , 0.05) (Fig. S3B), and mortality (Fig. S3A). Finally, CCR92/2
mice also demonstrated severe lung pathology including diffuse alveolar damage and prolonged loss of surfactant protein C (SFTPC) expression in AT2 cells, comparable to the wildtype controls (Fig. S3C to G). Analysis of the cytokine proﬁle in lungs by multiplex immune
assay showed increased subsets of cytokines and chemokines involved in promoting allergic
airway inﬂammation, including IL-6, CCL3, G-CSF, CCL2, IL-13, CXCL1, and CCL11 (Eotaxin)
(Fig. 6D). Flow cytometric analysis showed that in CCR92/2 mice there was a signiﬁcant
increase in CD41 T cells, CD81 effector T cells, CD11b1 dendritic cells (DCs), and eosinophils
at 6 dpi, consistent with an airway inﬂammatory response (Fig. 6D to E). In summary, these
data support an important role of CCR9 in protection against severe sarbecovirus disease.
Cxcr6 regulates SARS-CoV MA15 and SARS-CoV-2 MA10 pathogenesis in mice.
As the Chr9 locus (HsR26 and HsR30) also contained variants segregating in Cxcr6 that
might contribute to reduced gene expression and severe disease, we also infected Cxcr6deﬁcient (CXCR62/2) and aged-matched controls of both sexes with SARS-CoV-MA15 and
followed the mice for 7 days. We detected no signiﬁcant differences in weight loss
(Fig. S4B) but signiﬁcant higher viral load, congestion scores, prolonged pulmonary dysfuntion (as measured by whole body plethysmograhy), and increased mortality (Fig. S4C
to F). The mortality rate in CXCR62/2 was signiﬁcantly increased with 100% mortality by
7 dpi compared to 70% in the control mice and a median survival rate of 4 dpi compared
to 6 dpi in the control mice (Fig. S4F). We then evaluated whether CXCR62/2 also serves as
a susceptibility gene for SARS-CoV-2 MA10 infection. CXCR62/2 mice showed more severe
disease progression associated with signiﬁcant weight loss (.20%) (P , 0.0001 to
P , 0.0005), prolonged airﬂow restriction, and increased mortality (50%, not shown) compared to wild-type C57BL/6 controls (Fig. 7A and B) CXCR62/2 lungs also had signiﬁcantly
higher viral loads and elevated congestion scores (P , 0.005 for 4 dpi) (Fig. 7C and D),
compared to wild-type controls. Lung cytokine and chemokine analysis showed levels of
IL-6, CCL2, G-CSF, and CXCL1 that were signiﬁcantly elevated in CXCR62/2 compared to
wild-type infected mice (Fig. 7E). The composition of inﬁltrating cells into the lungs (Fig. 7F
and G) of CXCR62/2 mice greater numbers of CD41 T cells (Fig. 7F), alveolar macrophages,
inﬂammation-promoting CD11b1 DCs, and monocytes at 4 dpi (Fig. 7G), consistent with
an increased inﬂammatory airway response.
DISCUSSION
Emerging viruses represent an ongoing threat to human health and economic stability. As many emergence events are characterized by small outbreaks that are not
amendable to GWAS, new strategies are needed to predict and understand how host
genetic variation might regulate disease severity. Infectious diseases have shaped the
natural genetic variation in the genomes of mammals. Although highly penetrant
monogenic traits have been described that regulate disease severity in humans, most
viral diseases likely are regulated by complex genetic traits (42–45). Novel viruses regularly emerge from zoonotic reservoirs to replicate and colonize one or more new mammalian hosts. Consequently, evolution may select for common susceptibility loci and
genes that regulate disease severity across species, although this hypothesis remains
unproven (42, 46–49). The successive emergence of genetically distinct sarbecoviruses
in 2002 and 2019, which replicate in and cause severe disease in multiple mammalian
hosts, provide an opportunity to determine the extent to which common or unique
susceptibility loci regulate disease severity across species. During the ﬁrst SARS-CoV
epidemic, no consensus was reached on the human loci and genes that inﬂuence
disease severity (50).
FIG 6 Legend (Continued)
chemokine/cytokine analysis; n = 12 CCR92/2 and n = 13 C57BL/6NJ with n = 2 each for mock, n = 6-7 for 4 dpi, and n = 5-6 for 6 dpi for analysis of
inﬁltrating cells). Data were analyzed using 2-way ANOVA with multiple comparison (weight and PenH) and Mann-Whitney test (viral titer, congestion
score, cytokine/chemokine, and inﬁltrating cells); *, P , 0.05; **, P , 0.005; ***, P , ; 0.0005; ****, P , 0.0001.
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FIG 7 Cxcr6 regulates SARS-CoV-2 MA10 pathogenesis in mice. To study the effect of Cxcr6 on the susceptibility to SARS-COV-2 infection, groups of agematched CXCR62/2 mice were infected with 1  105 PFU SARS-CoV-2 MA10 and followed for several days for disease outcomes. (A) Weight loss of CXCR62/2
mice and C57BL/6J control mice. (B) PenH of CXCR62/2 mice and C57BL/6J control mice. (C) Lung viral titer of CXCR62/2 mice and C57BL/6J control mice on 2, 4,
and 7 dpi. (D) Congestion score of CXCR62/2 mice and C57BL/6J control mice on 2, 4, and 7 dpi. (E) Cytokine/chemokine distribution in the lung of CXCR62/2
mice and C57BL/6J control mice on 2, 4, and 7 dpi. (F) Composition of lung inﬁltrating immune cells in the lung of CXCR62/2 mice and C57BL/6J control mice on
4 dpi (15-18-week-old mice were infected with 1  105 PFU SARS-CoV-2 MA10; C57BL/6NJ: n = 15, n = 5 for 2 dpi, n = 5 for 4 dpi, n = 5 for 7 dpi; CXCR62/2:
n = 12 total, n = 4 for 2 dpi, n = 5 for 4 dpi, n = 3 for 7 dpi for weight loss, viral titer, congestion score, and chemokine/cytokine analysis; C57BL/6NJ: n = 4 and
CXCR62/2: n = 4 for lung function analysis, n = 8–9 CXCR62/2 and n = 10 C57BL/6NJ with n = 2 each for mock, n = 6–8 for 4 dpi for analysis of inﬁltrating cells).
Data were analyzed using 2-way ANOVA with multiple comparison (weight and PenH) and Mann-Whitney test (viral titer, congestion score, cytokine/chemokine,
and inﬁltrating cells); *, P , 0.05; **, P , 0.005; ***, P , 0.0005; ****, P , 0.00001.

Recent GWAS in humans identiﬁed a locus 3p21.31, associated with susceptibility to
respiratory failure, severe disease outcome, and hospitalizations after SARS-CoV-2
infection. This locus encompasses six genes, all of which showed strong signals in multiple GWAS studies: SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6, and XCR1, with the causative
signals between studies spread across these genes (14, 15, 32–34, 51). These genes are
differentially regulated in mild and severe human disease, suggesting the presence of
genetic variants that regulate gene expression (15, 16, 39–41). To date, none of these
genes have been deﬁnitively linked to disease severity after SARS-CoV-2 infection (15,
16, 39–41). This human locus shows conserved synteny with the proximal region of our
Chr9 multitrait QTL, HsR26 in mice, and shows similar genetic order and orientation of
all six candidate genes. Furthermore, in addition to nonsynonymous differences in
LZTFL1, CCR9, FYCO1, and SLC6A20A/B, regulatory differences were seen for genes in
this locus at baseline as well as in the context of infection. As such, it is likely that complex interactions between multiple candidates in this locus give rise to the observed
disease differences at HrS26 and present the intriguing possibility that some of these
regulatory differences underlie common disease mechanisms between mice and
humans.
Within the locus, we focused on two genes, Ccr9 and Cxcr6, as both are expressed
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at reduced levels in our parental susceptible parental strain and in vulnerable human
cases (16, 39, 40). Gene deletions represent extreme reductions in expression and loss
of function, which differ from the subtle impact that allele variation in noncoding or
coding regions might have. However, these studies represent an important ﬁrst step
toward elucidating the genetic drivers of sarbecovirus disease severity and highlight a
rationale for future study of CCR9 and CXCR6 allele variants. CCR9 is expressed by T
cells, DCs, monocytes/macrophages, and eosinophils and is a receptor for CCL25 (52).
The CCR9/CCL25 axis functions in homeostasis, inﬂammation, and inﬂammation-associated diseases including early respiratory allergic inﬂammation, asthma, chronic inﬂammatory bowel diseases, and organ ﬁbrosis (53). CXCR6 is also expressed by T cells and
serves as a homing mediator for resident memory T cells (TRM). Previous studies have
shown that CXCR62/2 mice have decreased lung resident TRM cells, which is associated
with increased host control of Mycobacterium tuberculosis and inﬂuenza virus infections
(54). Both CCR9 and CXCR6 are involved in recruiting T cells and regulating inﬂammatory responses during lung infection. Importantly, SARS-CoV-2 infection stimulated
distinct yet overlapping inﬁltrating cell populations and cytokine and chemokine signatures in CCR92/2 and CXCR62/2 mice. SARS-CoV-2-infected CCR92/2 mice showed
severe disease progression, with an increased inﬂux of inﬂammatory macrophage/
monocyte cells, T cells, and eosinophils, coupled with a chemokine/cytokine proﬁle
that supports an allergic inﬂammatory response in the lung. SARS-CoV-2-infected
CXCR62/2 mice showed an inﬂux of inﬂammatory cells with expression of proinﬂammatory Th1-cytokines/chemokines in the lungs. As both genes are downregulated in
highly susceptible CC074 mice and in humans with severe respiratory failure, it is possible that both genes, as well as other genes under the QTL, contribute to vulnerability
to SARS-CoV-2 infection in mice. Detailed genetic mapping studies in human cohorts have
implicated a 59 synonymous mutation in the noncoding region of the LZTFL1 gene, which
contributes to the downregulation in expression, although it still remains uncertain if this
gene directly modulates severe human or mouse disease outcomes (41).
Here, we demonstrate that mice lacking Ccr9 or Cxcr6 expression developed severe
disease most likely driven by excessive inﬂammation. The increased numbers of proinﬂammatory monocytes in both the Ccr9- and Cxcr6-deﬁcient mice suggest a potential
mechanism for increased disease severity, as previous studies have implicated the levels of proinﬂammatory monocytes cells in lethal SARS-CoV infection (55). Lack of CCR9
enhances disease severity, this gene likely has an important protective function during
SARS-CoV, HKU3-SRBD, and SARS-CoV-2 infection in mice. Our data also indicates that
lack of CXCR6 gene enhances disease severity, implicating a role in protecting against
lethal infection as well. In future studies, we plan to deﬁne the exact SNP(s) that regulate the differential expression levels and induction of Ccr9 and Cxcr6 and identify the
causal mechanisms underlying the observed disease outcomes associated with the
human GWAS results, as well as our HrS26 results.
Rich and complex data sets such as described herein enable comparisons with
human GWAS studies mapping QTL after SARS-CoV-2 infection. Our data support the
idea that there are shared disease susceptibility loci in both human and mice. We provide evidence from our mouse studies that the HrS26 locus is involved in disease outcomes across multiple genetically distinct sarbecoviruses. Our study highlights the
power of using animal GRPs to understand the role of host genetic variation on infectious diseases, generate new models of differential disease, probe the role of individual
genes in disease progression, and provide mechanistic insight into the role of speciﬁc
host genes and viral strains in regulating pathogenesis across species. In appropriately
selected large population screens such as the entire CC resource, highly penetrant
genetic variants that impact disease outcome can be readily identiﬁed. In contrast, targeted mapping crosses between highly discordant CC RI strains can identify more
complex genetic networks such as variants that are penetrant only in the context of
speciﬁc genetic backgrounds, or epistatic (gene-gene) interaction networks. In addition, the multiple loci we identiﬁed, as well as unexplained heritability in this cross,
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suggest that CoV disease and immunity are complex polygenic traits, with the accumulation of variants across many loci driving disease susceptibility. Our studies represent
a comprehensive comparison of susceptibility loci for sarbecoviruses in two different
mammalian hosts, identify a large collection of susceptibility loci and candidate genes
and alleles that regulate multiple aspects type-speciﬁc and cross-CoV pathogenesis,
validate a potential role for the CCR9 and/or CXCR6 in regulating SARS-CoV-2 disease
severity, and provide a resource for community-wide studies. The evidence supporting
a common-susceptibility loci harbored in CC074 mice and in highly vulnerable human
populations provides new opportunities for studying sarbecovirus-host interactions,
inﬂammation, and immunity in genetically relevant mammalian models, potentially
revealing new insights into acute and chronic disease progression and providing a
potentially more relevant model for evaluating immunotherapeutic control of lifethreatening sarbecovirus infection outcomes.

Cells and viruses. Recombinant mouse-adapted SARS-CoV MA15, HKU3-SRBD-MA (HKU3-SRBD MA),
and SARS-CoV-2 MA10 virus were generated as described previously (10, 18, 35). For virus titration, the
caudal lobe of the right lung was homogenized in PBS, resulting homogenate was serial-diluted and inoculated onto conﬂuent monolayers of Vero E6 cells (ATCC CCL-81), followed by agarose overlay. Plaques
were visualized with overlay of Neutral Red dye on day 2 (SARS-CoV MA15, HKU3-SRBD MA) or day 3
(SARS-CoV-2 MA10) postinfection. All virological studies were conducted under BSL3 conditions, and
personnel wore appropriate personal protective gear.
Mouse studies and in vivo infections. Mouse studies were performed at the University of North
Carolina (UNC) (animal welfare assurance no. A3410-01) using protocols approved by the UNC
Institutional Animal Care and Use Committee (IACUC). Animal studies at Washington University were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocols were approved by the IACUC at the
Washington University School of Medicine (assurance no. A3381-01).
Mouse studies were divided into three major classes: F2 intercross mice, CC mice, and inbred wild-type
or gene-edited mice. CC mice were purchased directly from the UNC Systems Genetics Core Facility at 3 to
5 weeks of age and acclimated for a week in the BSL3 before challenge. We contracted with the Systems
Genetics Core Facility at UNC to generate the F2 mice used in this study. First, F1 mice between CC011 and
CC074 were generated by cross males and females in both directions, and then the F2 mice were bred in all
4 possible F1 x F1 combinations, to ensure appropriately balanced sex Chromosome and parent-of-origin
effects. F2 mice (226 males, 177 females) were weaned such that littermates were randomized to different
experimental cages to reduce litter or batch effects on the study, and mice were transferred at 5 to 6 weeks
of age to the laboratory for infection between 9 and 12 weeks of age. For studies in genetically deﬁned
knockout mice, 15-18 - week-old CCR92/2 mice (strain 027041), CXCR62/2 mice (strain 005693) C57BL/6NJ
mice (strain 005304), and C57BL/6J (strain 000664) were purchased from Jackson Laboratory, and the genotype of these mutant mice were conﬁrmed via genotyping on the MiniMUGA array (Neogen, Inc.). CC mice
and CC-F2 mice were inoculated with 1  104 PFU (CC-F2 with SARS-CoV MA15 and CC mice with either
SARS-CoV MA15 or SARS-CoV-2 MA10, respectively). For infection, CXCR62/2, CCR92/2, and appropriate
C57BL/6 control mice were anesthetized with a mixture of ketamine/xylazine and inoculated intranasally (in
both nostrils) with 1  105 PFU of either SARS-CoV MA15, SARS-CoV-2 MA10, or HKU3-SRBD MA in 50 m L of
PBS. Body weight, mortality, and pulmonary function by whole body plethysmography (56) were monitored
daily as indicated. At the designated time points, mice were euthanized and gross pathology (congestion
score) of the lung was assessed and scored on a scale from 0 (no lung congestion) to 4 (severe congestion
affecting all lung lobes). Then, lung tissue was harvested for titer and histopathology analysis, and blood
samples were harvested for analysis of immune cells. Samples were stored at 280°C until homogenized and
titered by plaque assay as described above. Peripheral blood was diluted 1:5 in PBS/EDTA and analyzed with
the VetScan HM5 as previously described (57). Histopathology samples were ﬁxed in 10% phosphate-buffered formalin for 7 days before parafﬁn embedding, section stained with hematoxylin and eosin, and scored
for DAD and acute lung injury as previously described by our group (58).
Flow cytometry analysis of immune cell inﬁltrates. For analysis of lung tissues, mice were perfused
with sterile PBS, and the right inferior lung lobes were digested at 37°C with 630 m g/mL collagenase D
(Roche) and 75 U/mL of DNase I (Sigma-Aldrich) for 2 h. Single cell suspensions were preincubated with Fc
Block antibody (BD PharMingen) in PBS 1 2% heat-inactivated FBS for 10 min at room temperature before
staining. Cells were incubated with antibodies against the following markers: eﬂuor506 Viability Dye (650866-14; Thermo Fisher), BUV395 anti- CD45 (Clone 30-F11,;BD Biosciences), BV711 anti-CD11b (Clone M1/
70; Biolegend), APC-Cy7 anti-CD11c (Clone HL3; BD Biosciences), BV650 anti-Ly6G (Clone 1A8; Biolegend),
Paciﬁc Blue anti-Ly6C (Clone HK1.4; Biolegend) FITC anti-CD24 (Clone M1/69; Biolegend), PE anti-Siglec F
(Clone E50-2440; Biolegend), PE-Cy7 anti-CD64 (Clone X54-5/7.1; Biolegend), AF700 anti-MHCII (Clone M5/
114.15.2; Biolegend), BV421 anti-CD3 (Clone 17A2; Biolegend), BV785 anti-CD4 (Clone GK1.5; Biolegend), APC
anti-CD8a (Clone 53-6.7; Biolegend), BV421 anti-B220 (Clone RA3-6B2; Biolegend), APC-Cy7 anti-CD44 (Clone
IM7; Biolegend), and BV605 anti-CD62L (Clone MEL-14; Biolegend). All antibodies were used at a dilution of
1:200. Cells were stained for 20 min at 4°C, washed, ﬁxed, and permeabilized for intracellular staining with
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Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to manufacturer’s instructions. Cells
were incubated overnight at 4°C with BV421 anti-Foxp3 (Clone MF-14; Biolegend) washed, reﬁxed with 4%
PFA (EMS) for 20 min, and resuspended in permeabilization buffer. Absolute cell counts were determined
using Trucount beads (BD). Data were acquired on a ﬂow cytometer (BD-X20; BD Biosciences) and analyzed
using FlowJo software (Tree Star) (Fig. S5).
Cytokine and chemokine protein analysis. The small center lung lobe of each mouse was homogenized in 1 mL of PBS and brieﬂy centrifuged to remove debris. Fifty microliters of homogenate was
used to measure cytokine and chemokine protein abundance using a Bio-Plex Pro mouse cytokine 23plex assay (Bio-Rad) according to the manufacturer’s instructions.
Lung pathology scoring and RNA in situ hybridization/quantiﬁcation. Two separate lung pathology scoring scales, Matute-Bello and Diffuse Alveolar Damage (DAD), were used to quantify acute lung
injury (58). For Matute-Bello scoring samples were blinded and three random ﬁelds of lung tissue were
chosen and scored for the following: A: neutrophils in alveolar space (none = 0, 1 to 5 cells = 1, .5
cells = 2); B: neutrophils in interstitial space (none = 0, 1 to 5 cells = 1, .5 cells = 2); C: hyaline membranes (none = 0, one membrane = 1, .1 membrane = 2), (D) Proteinaceous debris in air spaces
(none = 0, one instance = 1, .1 instance = 2); and E: alveolar septal thickening (, 2 Å; mock thickness = 0, 2 to 4 Å; mock thickness = 1, .4 Å; mock thickness = 2). Scores from A to E were put into
the following formula score = [(20  A) 1 (14  B) 1 (7  C) 1 (7  D) 1 (2  E)]/100 to obtain a lung
injury score per ﬁeld and then averaged for the ﬁnal score for that sample.
In a similar manner, DAD scoring was obtained by evaluating three random ﬁelds of lung tissue that
were scored for the in a blinded manner for the following: 1 = absence of cellular sloughing and necrosis, 2 = uncommon solitary cell sloughing and necrosis (1 to 2 foci/ﬁeld), 3 = multifocal (3 1 foci) cellular
sloughing and necrosis with uncommon septal wall hyalinization, or 4 = multifocal (.75% of ﬁeld) cellular sloughing and necrosis with common and/or prominent hyaline membranes. To obtain the ﬁnal DAD
score per mouse, the scores for the three ﬁelds per mouse were averaged.
RNA-ISH was performed on parafﬁn-embedded 5-m m tissue sections using the RNAscope Multiplex
Fluorescent Assay v2 according to the manufacturer’s instructions (Advanced Cell Diagnostics). Brieﬂy,
tissue sections were deparafﬁnized with xylene and 100% ethanol twice for 5 min and 1 min, respectively, incubated with hydrogen peroxide for 10 min and in boiling water for 15 min, and then incubated
with Protease Plus (Advanced Cell Diagnostics) for 15 min at 40°C. Slides were hybridized with custom
probe (RNAscope Probe-Mm-Sftpc-C2; cat no. 314101-C2) at 40°C for 2 h, and signals were ampliﬁed
according to the manufacturer’s instructions. Stained sections were scanned and digitized by using an
Olympus VS200 ﬂuorescence microscope with a 40  1.35 NA objective. Images were imported into
Visiopharm Software (version 2020.09.0.8195) for quantiﬁcation. Lung tissue and Sftpc signal were quantiﬁed using a customized analysis protocol package to (i) detect lung tissue using a decision forest classiﬁer, and (ii) detect the probe signal based on the intensity of the signal in the channel corresponding to
the relevant probe (Sftpc). All slides were analyzed under the same conditions. Results were expressed
as the area of the probe relative to total lung tissue area.
Mouse DNA genotyping. CC011, CC074, their F1 progeny, the F2 cross, CXCR62/2, CCR92/2 mice,
and appropriate controls were genotyped on the MiniMUGA genotyping array (28, 37). Genomic DNA
was isolated from tail-clips of animals using the Qiagen (Hilden, Germany) DNeasy blood and tissue kit.
Then, 1.5 m g was sent to Neogen (Lincoln, NE) for processing. We ﬁltered the genotypes upon return for
informativeness within this cross. To be considered as valid, the marker had to have one homozygous allele in all CC011 mice genotyped, the alternate homozygous allele in all CC074 mice genotyped, and the
appropriate call in all F1 animals (H calls on the autosomes, an H call in females on the X chromosomes,
and the relevant homozygous call in male F1s). This ﬁltering reduced the ;10,800 SNPs on the
MiniMUGA array to 2,821 informative markers.
QTL mapping and statistical analyses. We used R/QTL for genetic mapping (59, 60). Brieﬂy, after
appropriate data transformations, we used the scanone function to determine the strength of the
regression of phenotypes on genotypes at each of the informative markers in the cross. Signiﬁcance
thresholds were determined by running 1,000 permutations, scrambling the relationship between phenotypes and genotypes, providing an appropriate threshold of signiﬁcance that is robust to the phenotype distribution and allele frequencies. For phenotypes where we identiﬁed multiple QTL, we ensured
that long-range linkage disequilibrium was not driving these observations by ﬁtting multifactor ANOVAs
with single QTL and with sets of loci. Only loci for which there was a statistically signiﬁcant improvement
in ﬁt for the full model were kept.
Data availability. All data supporting the ﬁnding of this study are available within the article and
are available from the corresponding authors upon request.
Statistical analysis. The number of independent experiments and technical replicates are indicated
in the relevant ﬁgure legends. Two-way ANOVA with multiple comparison were used for weight loss and
lung function comparisons, log-rank was used for survival studies, and Mann-Whitney test was used for
viral titer, congestion score, okine/cytokine, inﬁlatrating cells, histophatholgy score, and gene expression
comparisons.
Code use. We used R/QTL for genetic mapping and the scanone function to determine the strength
of the regression of phenotypes on genotypes at each of the informative markers in the cross.
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